(5) Changes in the scope of consolidation
Accounting and measurement policies
Changes in the scope of consolidation
Overall, the impact of subsidiaries not consolidated due to immateriality on net sales, profit after tax, assets, and equity was less than 1% relative to the entire Group. The shares in these companies are reported in non-current financial assets (see Note (36) “Other financial assets”).
The scope of consolidation changed as follows in the reporting period:
Fully consolidated companies as of Dec. 31, 2019 |
|
|
|
335 |
|---|---|---|---|---|
Additions |
|
Companies established |
|
4 |
|
Acquisitions |
|
2 |
|
|
Materiality |
|
– |
|
Retirements |
|
Liquidations/mergers |
|
-8 |
|
Divestments |
|
-5 |
|
|
Immateriality |
|
-2 |
|
|
Loss of control |
|
– |
|
Fully consolidated companies as of Dec. 31, 2020 |
|
|
|
326 |
Subsidiaries rated at-equity as of Dec. 31, 2019 |
|
|
|
– |
Subsidiaries rated at-equity as of Dec. 31, 2020 |
|
|
|
1 |
Non-consolidated subsidiaries as of Dec. 31, 2019 |
|
|
|
33 |
Non-consolidated subsidiaries as of Dec. 31, 2020 |
|
|
|
33 |
The list of non-consolidated subsidiaries mainly comprises non-operating shelf companies as well as entities subject to liquidation procedures, which are subsequently measured at fair value through other comprehensive income. The company accounted for using the equity method is Syntropy Technologies LLC, United States, which was formed in fiscal 2020. This company generated sales of € 1 million in the year under review.
The list of shareholdings presents all the companies included in the consolidated financial statements as well as all of the shareholdings of Merck KGaA, Darmstadt, Germany (see Note (50) “List of shareholdings”).